MYGN, the Next AMGN

[NY4Ever]

Drug Development Pipeline--- MYGN
Our drug development efforts target cancer, Alzheimer's disease, thrombosis, HIV/AIDS and other viral diseases. In addition, we have a number of other lead optimization programs within these disease areas.

Molecule Therapeutic Area Status
Flurizan™ Alzheimer's Disease Phase 3
MPC-7869 Prostate Cancer Phase 2b
MPC-6827 Brain Cancer Phase 1
MPC-6827 Solid Tumors Phase 1
MPC-2130 Blood Cancers Phase 1
MPC-0920 Thrombosis Preclinical
MPI-49839 HIV/AIDS Preclinical
MPC-4505 Cancer Preclinical
MPI-42511 Cancer Preclinical
MPI-442691 Alzheimer's Disease Preclinical

[NY4Ever]

FMR reported a 10.18% stake in biopharmaceutical company Myriad Genetics (MYGN

The Next AMGN

[Karel]

Hi NY4Ever,

please keep your MYGN posts in one thread; it will be easier for others to follow developments.

Regards,

Karel

[NY4Ever]

Fantastic pipeline ready to explode. Very small float.

[NY4Ever]

Just a friendly reminder.

[NY4Ever]

Breaking out of its up channel.

[skiracer]

Breaking out of its up channel.

I'm in from $22.00 range. Was waiting for this. Nice move today. Also holding ELN from $13.85 and gold ETF GLD from $465 area. MYGN terrible fundamentals but alot in the pipeline.

[NY4Ever]

09-Feb-2006
1:00 PM ET Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
Event type: Corporate Presentation
Presenter: Peter D. Meldrum, President & CEO MYGN
Location: Grand Hyatt, New York, NY

[NY4Ever]

At J. P. Morgan conference, CEO Peter Meldrum was very excited about 6827 drug for metastatic brain cancer saying the people at M. D. Anderson feel the same way.

[NY4Ever]

My pick of the week and up almost 10% today on big volume and a good earnings report. More good news coming Thursday. 2.5 million shares short.

[NY4Ever]

My pick of the week and up almost 10% today on big volume and a good earnings report. More good news coming Thursday. 2.5 million shares short.>>

UPGRADE: JMP Securities from overweight to strong buy. Target 29.

[NY4Ever]

Up 17% this week thus far.

[NY4Ever]

MYGN has 39 million shares outstanding, 235 million in cash and marketable securities, 2.5 million shares short, a fast growing and very profitable PM business and a pipeline of which 3 drugs could be blockbusters of one billion plus. Cancer drug 6827 has a good chance of getting fast track status. Do your own research.

[Lyehopper]

Up 17% this week thus far.
Great pick dude!

[Jim Smith]

gotta give you props on this, you sniffed this one out....gap above resistance.....

[NY4Ever]

Load up the wagon.

[NY4Ever]

MYGN - the $500 monster. Yes, I am crazy --- crazy as a fox. LOL

[NY4Ever]

"If you come to a fork in the road, take it." Yogi Berra

Do I have to spoon feed you guys? LOL

[NY4Ever]

I don't buy any stock unless it has the capability to at least double, triple or preferably a 1000% move. That was the case with Haloid Xerox back in 1969,
Syntex in 1964, AMGN in 1988. What's in your wallet?

[NY4Ever]

--------------------------------------------------------------------------------

I don't buy any stock unless it has the capability to at least double, triple or preferably a 1000% move. That was the case with Haloid Xerox back in 1969,
Syntex in 1964, AMGN in 1988. What's in your wallet?>>

Make that read Haloid Xerox in 1959.

[spikefader]

Do I have to spoon feed you guys?
http://img113.imageshack.us/img113/7051/cork0pq.gif (http://imageshack.us)

[mrmarket]

Just a friendly reminder.


Up 11% since you first posted last month. Excellent call. Thanks.

[Lyehopper]

I don't buy any stock unless it has the capability to at least double, triple or preferably a 1000% move. That was the case with Haloid Xerox back in 1969,
Syntex in 1964, AMGN in 1988. What's in your wallet?
1964? Wasn't Syntex on the IBD 100 back in "66" ?

So you've only owned 4 HUUUUGE stocks in your lifetime....

fascinating.... we could use you as an advisor to the VTP.

[skiracer]

--------------------------------------------------------------------------------

I don't buy any stock unless it has the capability to at least double, triple or preferably a 1000% move. That was the case with Haloid Xerox back in 1969,
Syntex in 1964, AMGN in 1988. What's in your wallet?>>

Make that read Haloid Xerox in 1959.

There's been any number of stocks that have doubled, tripled, quadrupled, and more since 1998 or so and the only ones you can mention are the few from 30 years or more in the past. For a supposedly brilliant trader didn't you participate in any of the more recent ones.

[NY4Ever]

There's been any number of stocks that have doubled, tripled, quadrupled, and more since 1998 or so and the only ones you can mention are the few from 30 years or more in the past. For a supposedly brilliant trader didn't you participate in any of the more recent ones.>>

I participated in many which more than doubled after I bought them, but it would be the height of arrogance to list them all. One in 1970 I sold was Memorex at 172. That was the TOP! I got out of all my techs at the height of the bubble though I didn't sell at the top. The only investors who buy at the bottom and sell at the top are liars. Example: Sold EMC at 75 and it immediatedly went over 100. Not about to list all my winners and yes there were a few losers which resulted from trying to be cute by trading in and out.
Missed out on GOOG until very late but did okay. My current home run candidate for the next 5 years is MYGN.

[Lyehopper]

My current home run candidate for the next 5 years is MYGN.
Can't argue with that.... Thanks for the pick DUDE!

What else do you like NY4Ever?

http://img355.imageshack.us/img355/1246/mygn4sg.png (http://imageshack.us/)

[NY4Ever]

What else do you like NY4Ever? >> Actually, I am not a trader. I am basically a long term investor who looks for home run stocks. I only trade when I am bored. LOL When I get another special situation, I'll let you know.

[NY4Ever]

40 - 60 - 80 - 100 - 125 - 500. Load up the wagon.

[DSteckler]

<< I am basically a long term investor who looks for home run stocks. >>

Yet on AOL you said you never bought stocks, only bonds. So which is it?

[NY4Ever]

Fellas, I left the AOL board because of Steckler. I see he has decided to impugn my integrity on this board. Unless he is thrown off, I won't be back. Good luck with your investrments.

[Lyehopper]

Fellas, I left the AOL board because of Steckler. I see he has decided to impugn my integrity on this board. Unless he is thrown off, I won't be back. Good luck with your investrments.
hmmmmmmm Steckler struck a nerve.... Don't be such a wimp NY4Ever....

[Adam]

NY4Ever,

I do enjoy your posts and am sure others do to. Steckler loves to get under your skin, he can only do that if you let him.

I'm in on the MYGN with you and am counting on your future input. Please stick around.

[skiracer]

Fellas, I left the AOL board because of Steckler. I see he has decided to impugn my integrity on this board. Unless he is thrown off, I won't be back. Good luck with your investrments.

I would strike back or answer the question and put it to an end. But better striking back. We haven't had a good dogfight here in a couple of days.

[NY4Ever]

I do enjoy your posts and am sure others do to. Steckler loves to get under your skin, he can only do that if you let him.>>

I thought this board would be different, but apparently people like Steckler who is nothing more than a liar and a coward is free to humiliate anyone he so chooses. If you have any integrity at all, you will throw him off the board.
I Have a standing wager with him for $100,000 that I am a retire V-P from one of the largest investment banking firms on Wall Street I was also made a partner before the firm went public at age 38. Steckler hasn't the guts to call me on this bet. He just likes to belittle people and considers himself the pied piper of the board along with Mr. Market. The difference is that Mr. Market is courteous.

[mrmarket]

I do enjoy your posts and am sure others do to. Steckler loves to get under your skin, he can only do that if you let him.>>

I thought this board would be different, but apparently people like Steckler who is nothing more than a liar and a coward is free to humiliate anyone he so chooses. If you have any integrity at all, you will throw him off the board.
I Have a standing wager with him for $100,000 that I am a retire V-P from one of the largest investment banking firms on Wall Street I was also made a partner before the firm went public at age 38. Steckler hasn't the guts to call me on this bet. He just likes to belittle people and considers himself the pied piper of the board along with Mr. Market. The difference is that Mr. Market is courteous.

Did you hate your commute. I worked in mid-town for 6 years and would have quit my job if I had to go one month more. Congrats on your retirement.

Every cloud has a silver lining. There is something I like in what everyone has to say here.

[Lyehopper]

I would strike back or answer the question and put it to an end. But better striking back. We haven't had a good dogfight here in a couple of days.
I'm with you Ski.... I wanna see a fistfight.... I got $25 on Steckler.

[Adam]

Save the drunken fist fights for after the convention everyone!!!

[NY4Ever]

Stock of the week.

[spikefader]

Stock of the week.MYGN?
http://img378.imageshack.us/img378/5403/mygnmar60cv.gif (http://imageshack.us)

[spikefader]

http://img413.imageshack.us/img413/4042/mygnlong8xr.gif (http://imageshack.us)

[NY4Ever]

Stock at 25.83 as of 2:55. A bargain. Still the stock of the week.

[NY4Ever]

"Buying a stock without inside information is like buying cattle in the moonlight" author unknown

[gerihearne]

Stock at 25.83 as of 2:55. A bargain. Still the stock of the week.

How far do you think mygn will run?
________
cheap volcano vaporizer (http://vaporizers.net/volcano-vaporizer)

[NY4Ever]

How far do you think mygn will run?>> This stock is a long term investment covering the next 5 years. That said, very short term I am looking for 29 -30 with a move to 40 by the end of June.

[mrmarket]

How far do you think mygn will run?>> This stock is a long term investment covering the next 5 years. That said, very short term I am looking for 29 -30 with a move to 40 by the end of June.


It certainly looks that way!

[NY4Ever]

08-Mar-2006
3:50 PM PST Fifth Annual JMP Securities Research Conference
Event type: Corporate/Financial Presentation
Presenter: Gregory C. Critchfield, M.D., President of Myriad Genetics Laboratories, Inc.
Location: The Ritz-Carlton, San Francisco, CA

[NY4Ever]

Word of caution. Continue to accumulate but use limit orders. Very thin stock and the specialists will kill you if you place market orders in excess of 500 shares.

[Websman]

I soaking in all of your valuable advice NY4ever. Thanks for everything!

[NY4Ever]

AMGN only had around 40 million shares when I first got involved. It now has 1,234,320,000 shares. Just a bit of trivia.

[Tatnic]

Stock at 25.83 as of 2:55. A bargain. Still the stock of the week.

How do you define bargain in a biotech? Do you mean by stock price or potential down the road? All I can think of is that guy on EI who bet the ranch on VPHM, remember him? That particular stock looks terrible now although it could go either way at this point. He was so passionate about that company's prospects...I'd be interested to see how he feels about it now.

ps...MYGN does indeed have a powerfully strong chart, but so did VPHM which at one point traded over 60% above it's 40 week.

[NY4Ever]

How do you define bargain in a biotech? Do you mean by stock price or potential down the road? >>

A bargain in any stock, not just a biotech, is when the reward is ten times greater than the risk. This was true of Haloid Xerox at 28 in 1959, Dell in April 1998, Amgn in 1988, Syntex in 1963 and many many more. Right now I equate MYGN with AMGN when they both had only 40 million shares outstanding and AMGN hadn't as yet had one drug approved.

[NY4Ever]

Very, very smart buyer all day today in this stock. Very impressive.

[RL]

I'm In looking for a good move up

[NY4Ever]

March 10

Firm gambles on Alzheimer's drug
Paul Elias

Associated Press

SAN FRANCISCO — It’s tragedy enough that Pat Williams’ mother has Alzheimer’s disease. But Williams is also terrified because her chances of inheriting the disease are much better than average.

So, Williams eagerly enrolled her 90-year-old mother last year in a massive, 1,600-patient, 18-month clinical trial testing an experimental drug made by the biotechnology company Myriad Genetics Inc. The drug, called Flurizan, slowed the mind-robbing disease in some of the 128 patients with mild Alzheimer’s participating in a smaller test.

Based on those results, the company has gambled millions of research dollars on the largest-ever Alzheimer’s drug trial. It aims to win an intense, international race among several biotech companies to find the first effective treatment for the 4.5 million Americans who suffer from the disease.

Myriad’s drug wasn’t effective for patients with moderate forms of the disease, so the company is targeting patients who have just been diagnosed. Scientists are also using the latest in brain imaging and genetic technology to develop tests to find people like Williams who have above-average chances of coming down with Alzheimer’s.

“I’m hoping they will have a miracle pill so that I won’t contract it,” said Williams, who lives in Boston.

Analysts predict the market for an Alzheimer’s drug could reach $4 billion annually by 2013 and success for Myriad would lift the company’s fortunes considerably. The Salt Lake City company is now best known for drilling deep into the Mormon community’s detailed genetic history to develop a popular breast cancer test.

At least two other companies are hot on Myriad’s tail.

Neurochem Inc., a Quebec company, has enrolled about 1,000 patients in its late-stage human test; and Ireland-based Elan Pharmaceuticals is almost as far in development with its own candidate.

“I want somebody to win this,” said Dr. Bill Thies, scientific director of the nonprofit Alzheimer’s Association. “I don’t particularly care if it’s Myriad or one of its competitors.”

All three are attempting to block production of the plaque-causing protein beta-amyloid. While the exact cause of Alzheimer’s remains a mystery, most researchers think a buildup of the protein in the brain is what leads to the disease.

Thies said results of the companies’ smaller human trials essentially showed they were safe and weren’t enough to make firm predictions about how effective they will be. But he said Myriad’s Flurizan has “some elements that look really positive.”

What is known is that the immune system of a healthy person gets rid of most of the amyloid. But something happens in Alzheimer’s patients that leads to a deadly amyloid buildup that coats and then kills brain cells.

Myriad is using an old class of anti-inflammatory drugs that includes the painkiller ibuprofen to prevent the buildup.

The company initially purchased commercial rights to Flurizan from its creators at Loma Linda University, near San Bernardino, because of its promise for fighting cancer. But it soon became clear in experiments with mice that the drug was also effective for Alzheimer’s as Myriad scientists made key tweaks to the drugs. The company continues to research Flurizan’s use in fighting prostate cancer.

“There is a feeling within the Alzheimer’s field that if you limit amyloid accumulation you will change the course of the disease,” Thies said.

The three drugs now approved in the United States for the disease temporarily alleviate Alzheimer’s symptoms, rather than treating them

Doctors are hopeful that experimental drugs like Flurizan can slow the march of Alzheimer’s, which is expected to claim a staggering 14 million in the United States by 2050 if no advances are made, according to Thies.

Myriad hustled Flurizan, which is a modified arthritis drug that is more than 20 years old, into final testing last year after the positive results of the smaller test.

If it succeeds, it will most likely spark interest in other anti-inflammatory drugs, including controversial painkillers like Merck’s Vioxx, which was pulled from the market in 2004 after it appeared likely to increase the risk of heart disease.

“These drugs are interesting and are real harbingers of a new class of Alzheimer’s medication,” said Dr. Robert C. Green, associate director of Boston University School of Medicine’s Alzheimer’s Disease Center.

Green is treating Williams’ mother and leading Myriad’s trial. Data from the trial will probably be released sometime next year and the drug could be on the market by 2009, Myriad said.

Alzheimer’s is a considerable drain on the health care system because of the round-the-clock care the millions of patients require. Some estimates of the disease’s cost rise to $100 billion annually when caretaker costs and time are considered.

Williams’ mother, for instance, pays about $500 a month to attend an adult day center while Williams works as a legal secretary. If her disease progresses any more, she may have to go live in a nursing home.

Because of the typical design of such drug trials, Williams, and her mother Rose Turner, don’t know whether they’re receiving Myriad’s Flurizan or a dummy pill. Williams said it would be nice if her mother was receiving the drug, but they’re still proud to be in the study even if they’re receiving the placebo. That’s because Williams and millions of others are desperate for even a modicum of relief.

“If it’s going to help people with Alzheimer’s, then we’ve accomplished something special,” Williams, 53, said. “My mom right now is my new child.”

[NY4Ever]

Another good day with smart buying. Just as yesterday the buyer was in at 26.05 most of the day, today he was in all afternoon with a 26.25 bid. In the final 10 minutes he moved the stock higher to close near its high for the day and only 7 cents short of its 52 week high. As for the general market my comments are as follows: At 3:15 the Dow was up 64, the Nasdaq up 3.98 and the S & P up 5.42. When I was on Wall Street we used to call the final 45 minutes of action up to the painters. This was called painting the tape and that is exactly what we got today -- making the market look better than it really is by closing it strong.

[NY4Ever]

Press Release Source: Myriad Genetics, Inc.


Myriad Genetics' Follow-on Study of Flurizan Demonstrates Continued Benefit in Alzheimer's Disease
Sunday March 12, 9:30 am ET
Flurizan Continues to Slow Decline in Cognition, Behavior and Daily Activities Through 21 Months


SALT LAKE CITY, March 12 /PRNewswire-FirstCall/ -- Myriad Genetics, Inc. (Nasdaq: MYGN - News; www.myriad.com) announced today that data from its Phase 2 follow-on study of Flurizan(TM) in patients with mild Alzheimer's disease is being presented at the 19th annual meeting of the American Association of Geriatric Psychiatry. The data suggest that study participants on 800 mg BID of Flurizan continued to demonstrate increasing benefit through month 21 in the area of cognition and memory loss and that they maintained more of their global function and activities of daily living than those on 400 mg BID of Flurizan or than the projected placebo. Results of the Phase 2 study and a summary of the 9-months of follow-on data were presented by Daniel Christensen, M.D., Clinical Professor of Psychiatry, Clinical Professor of Neurology and Adjunct Professor of Pharmacology at the University Neuropsychiatric Institute, Salt Lake City, Utah

[Adam]

Thank you for the informing post. I entered my option position a week or two ago after reading many of your posts. Currently I'm sitting on 39% profit and expirations in January. Obviously there's plenty of time left to sell and reenter. Will it hold the gap? Just your opinion, I know your trading objectives and that question may not be much intrest to you.

[NY4Ever]

. Will it hold the gap? Just your opinion, I know your trading objectives and that question may not be much intrest to you.>>

MYGN traded as high as 32 pre-market yesterday but ran into a lot of selling all day right from the opening. It could very easily close its gap around the 26.45 level, but that would just be a buying opportunity. I am not trading this stock.

[NY4Ever]

Company Symbol Brokerage Firm Reiterated Rating: Target
Myriad Genetics MYGN First Albany Buy

[NY4Ever]

First Albany target raised from 29 to 32.

[NY4Ever]

Piper raises target from 24 to 34.

[NY4Ever]

The big mystery, as I see it, is who is so stupid to sell this stock. Once again, in the last few minutes of trading a good buyer stepped in and took in quite a bit of stock at 27.50 while closing it within a penny of its high for the day. Stock continues to be under very smart accumulation. My target for the end of March is 30, end of June 40, end of year 60 and I am being very conservative.

[NY4Ever]

While most biotechs fell today, and some sharply, MYGN continues to show superb tape action. The stock continues under accumulation by very smart buyers. It is not too late to position this stock as the upside potential from current levels is 1000% and I consider the downside risk minimal. I have great expectations for the company's alzheimers drug, its 6287 cancer drug and its HIV drug. This stock is another AMGN. The weak sellers are out. The smart buyers are not trading this stock. Buy it and put it away for the next 5 years.

[NY4Ever]

UPDATE:


Myriad Genetics' Follow-on Study of Flurizan Demonstrates Continued Benefit in Alzheimer's Disease
Myriad Genetics' Follow-on Study of Flurizan Demonstrates Continued Benefit in Alzheimer's Disease

Flurizan Continues to Slow Decline in Cognition, Behavior and Daily Activities Through 21 Months

SALT LAKE CITY, U.T. -- March 16, 2006 -- Myriad Genetics, Inc. announced that data from its Phase 2 follow-on study of Flurizan™ in patients with mild Alzheimer's disease is being presented at the 19th annual meeting of the American Association of Geriatric Psychiatry.

The data suggest that study participants on 800 mg BID of Flurizan continued to demonstrate increasing benefit through month 21 in the area of cognition and memory loss and that they maintained more of their global function and activities of daily living than those on 400 mg BID of Flurizan or than the projected placebo.

Results of the p2 study and a summary of the 9-months of follow-on data were presented by Daniel Christensen, MD, Clinical Professor of Psychiatry, Clinical Professor of Neurology and Adjunct Professor of Pharmacology at the University Neuropsychiatric Institute, Salt Lake City, Utah.

The data suggest that during the follow-on period from months 12 to 21, the benefit of Flurizan on the measures of Alzheimer's disease increases in terms of both effect size and significance, the longer patients remain on Flurizan. The efficacy of Flurizan in the first 12 months of the Phase 2 was measured as the difference between the rates of decline, or slopes, of the treated groups and the placebo group.

In the follow-on study, because the placebo group has been randomized into the treatment arms, we are measuring the difference between the slopes of the treated groups and the slope of the placebo group during the first 12 months, extended through 21 months. The statistical significance of the resulting difference in slopes, or the effect size, is computed as a p value.

As measured by the performance of activities of daily living (ADCS-ADL), by patients taking 800 mg of Flurizan BID, there was a 52% effect size compared with the projected slope of the placebo at 21 months, with a significant value of P =.029. In terms of the patient's global function at 21 months, the CDR-sb scale showed a 75% effect size, with a value of P =.0007, also significant. These data suggest that there is a substantial benefit from Flurizan on activities of daily living and global function, and that the benefit is increasing over time.

The effect of Flurizan in improving cognitive decline, as measured on the ADAS-cog scale, has also increased, as shown by the effect size of 60% at 21 months. All three of the measures suggest sustained benefit from Flurizan in patients with mild Alzheimer's disease.

At 21 Months
Effect Size* (Significance, by slope analysis)
Activities of Daily Living 52% (P =.029)
Global Function 75% (P =.0007)
Cognition 60% (P =.096)
* Cohen's d

"The 21 months of data give us further confidence in the power of our Phase 3 trial to demonstrate a benefit from Flurizan for Alzheimer's patients," said Adrian Hobden, Ph.D., President of Myriad Pharmaceuticals, Inc. "The results are additional evidence that Flurizan appears to be modifying the course of the underlying disease process."

About the Phase 2 Follow-on Study of Flurizan
After completion of Myriad's 12-month Phase 2 trial of Flurizan, study participants in Canada were given the option to continue in a follow-on study. A total of 81% of those participants opted to join the follow-on study. Those participants who had previously received placebo during the Phase 2 trial were randomized into the 400 mg BID group or the 800 mg BID group, and are therefore not included in the data presented during the follow-on study. Participants who were taking Flurizan in the initial Phase 2 trial continued on the same dose that they had been receiving. However, neither patients and their caregivers, nor their doctors, know which arm of the study the patients are in. During the Phase 2, the observed patient dropout rate was lower than anticipated by the study plan and that trend has continued through 21 months.

About Myriad's Phase 3 Trial of Flurizan in Alzheimer's Disease
Based on the positive Phase 2 results, Myriad is enrolling patients with mild Alzheimer's disease for a Phase 3 trial, at 130 centers across the United States. This enrollment is proceeding on schedule. The Phase 3 trial is a double blind, placebo-controlled trial. Patients will be randomized into one of two arms, receiving either 800 mg of Flurizan or placebo twice daily for the duration of the 12-month trial period. The study is designed to determine Flurizan's ability to reduce the rate of cognitive decline and activities of daily living in patients with mild Alzheimer's disease, as measured by the ADAS-cog test and the change in ADCS-ADL, respectively. Information on participation is available by calling (888) 459-4888.

About Flurizan
Flurizan is the first in a new class of drug candidates known as Selective Amyloid beta-42 Lowering Agents (SALAs). Flurizan lowered levels of Abeta42 in cellular assays and animal models. Abeta42 is the primary constituent of senile plaque that accumulates in the brain of patients with Alzheimer's disease. It is thought to be the key initiator of Alzheimer's disease, since Abeta42 has the greatest tendency to aggregate, cause neuronal damage and initiate amyloid deposits in the brain. Most genetic mutations that cause early-onset Alzheimer's disease appear to do so by increasing production of Abeta42. Myriad believes that Flurizan is the most advanced drug candidate that inhibits the production of Abeta42 to be evaluated in a clinical trial for the treatment of Alzheimer's disease.


Flurizan is a trademark of Myriad Genetics, Inc. in the United States and other countries.

[NY4Ever]

Ubs --- Buy

[NY4Ever]

UBS initiated buy today with 35 target just one more positive development.
But that is nothing compared to what will be announced prior to the end of June. On target for 30 this month. Like taking candy from a baby. Stock is a homerun.

[mrmarket]

UBS initiated buy today with 35 target just one more positive development.
But that is nothing compared to what will be announced prior to the end of June. On target for 30 this month. Like taking candy from a baby. Stock is a homerun.

Agreed..that would be consistent with what the rest of the financial services studs (GS, Bear) have been showing recently.

Good observation.

[gerihearne]

Agreed..that would be consistent with what the rest of the financial services studs (GS, Bear) have been showing recently.

Good observation.

are you talking about ubs ag ... kinda pricey ... 109.75 close ?

[Runner]

Here is longer-term chart (monthly)
http://img123.imageshack.us/img123/2304/mygnmonthly8lv.png (http://imageshack.us)

Daily
http://img116.imageshack.us/img116/2425/mygndaily7ve.png (http://imageshack.us)

[gerihearne]

Here is longer-term chart (monthly)
http://img123.imageshack.us/img123/2304/mygnmonthly8lv.png (http://imageshack.us)

Daily
http://img116.imageshack.us/img116/2425/mygndaily7ve.png (http://imageshack.us)


Runner, I can't find ubs ... can you tell me what its full name is?

[thebign1]

Runner, I can't find ubs ... can you tell me what its full name is?

Hello Geri, UBS is the analyst & the chart is for MYGN.

regards, thebign1

[gerihearne]

Hello Geri, UBS is the analyst & the chart is for MYGN.

regards, thebign1

i am such a novice! thanks, thanks!!

[Adam]

This has been a beautiful pick. I hope it continues just as you plan.

[DSteckler]

UBS is not an analyst per se, they're a banking and financial services group.

[NY4Ever]

This has been a beautiful pick. I hope it continues just as you plan.>>

You aint seen nothing yet.

[NY4Ever]

Another day with good buying suggesting a strong close. The real float is rapidly deminishing with only a little over 5 million shares in the hands of the public. Stock is acting very well today despite a weak biotech market. My target of 29 - 30 by the end of March right on course. Also, 40 by the end of June could be closer to 50. Best buy among all the biotechs for the next 5 years with a potential of a 1000% move. Truly another AMGN as time will prove.

[NY4Ever]

Stock a strong buy into today's selloff with the stock down 69 currently. No change in 29 - 30 end of month target.

[NY4Ever]

Why MYGN sold off yesterday:

Flaw Seen in Genetic Test for Breast Cancer Risk



By ANDY POLLACK
Published: March 22, 2006
The widely used genetic test for breast cancer risk can miss mutations that help cause the disease, according to a new study, a finding that is likely to increase the pressure to develop more thorough testing methods.

The test, which looks for mutations in genes called BRCA1 and BRCA2, missed them in about 12 percent of breast cancer patients from families with multiple cases of breast or ovarian cancer, according to the study's authors at the University of Washington.

Experts cautioned that the chances of such false negative results were much smaller for women who were not from such high-risk families, so that most women who tested negative had little cause for concern.

In addition, experts said that even Ashkenazi Jews, who have a relatively high incidence of mutations, tend to have specific types that are not likely to be missed by the test. In addition, if a woman is tested for the same specific mutation her mother has, the test is not likely to miss it if it is there.

Still, experts said women in families with multiple cases of breast and ovarian cancer should take precautions as if they had a mutation, even if none was found.

"Everyone who has a strong family history and is negative should be considering how negative that result really was," said Dr. Judy E. Garber, director of the cancer risk and prevention program at the Dana-Farber Cancer Institute in Boston.

The new study, being published in The Journal of the American Medical Association, is likely to increase the pressure on Myriad Genetics, which offers the test.

The company, based in Salt Lake City, has long been the focus of controversy because its patents give it a monopoly on the test, for which it charges as much as $3,000. Some geneticists say the monopoly has slowed development of better testing.

[gerihearne]

Why MYGN sold off yesterday:

Flaw Seen in Genetic Test for Breast Cancer Risk



By ANDY POLLACK
Published: March 22, 2006
The widely used genetic test for breast cancer risk can miss mutations that help cause the disease, according to a new study, a finding that is likely to increase the pressure to develop more thorough testing methods.

...

The company, based in Salt Lake City, has long been the focus of controversy because its patents give it a monopoly on the test, for which it charges as much as $3,000. Some geneticists say the monopoly has slowed development of better testing.

NY4EVER: Does this change your thoughts on target ?

Cordially,
Geri

[Jim Smith]

MYGN is a perfect example of why I don't hold stocks going into year over year negative seasonality....

[DSteckler]

That's gotta hurt.

The fact that it held its 50DMA is a bright spot. If that lets go there's support just above 22.

[NY4Ever]

NY4EVER: Does this change your thoughts on target ? >>

Had to go out of town on personal business and just got back. Missed all the excitement. Stock is a strong buy but this was a setback we didn't need.
I see that JMP, Piper and UBS all came out defending their buys on the stock.
I see today's action as an opportunity for the shorts to cover. Not sure if we will see 29 - 30 by the end of this month, but a move back to 28 is very possible. Only the amateurs sold today. Nothing has changed. Just a better buying opportunity. Stock should easily reach 40 by the end of June.

[New-born baby]

NY4EVER: Does this change your thoughts on target ? >>

Had to go out of town on personal business and just got back. Missed all the excitement. Stock is a strong buy but this was a setback we didn't need.
I see that JMP, Piper and UBS all came out defending their buys on the stock.
I see today's action as an opportunity for the shorts to cover. Not sure if we will see 29 - 30 by the end of this month, but a move back to 28 is very possible. Only the amateurs sold today. Nothing has changed. Just a better buying opportunity. Stock should easily reach 40 by the end of June.

I agree. Today the rule was applied to MYGN: gaps like to be filled. Those power gaps up the last couple of months all got filled today. That bullish hammer candle today just screams to me that MYGN moves up tomorrow. Not afraid of its action today; just glad I didn't have to watch it :D In any case, touching the 50 day has been quite healthy in the past; I suspect it will be so again. I think this thing is a buy, but my target is lower than $40. I think $36. Here's the daily: the weekly is even prettier.
http://img228.imageshack.us/img228/9018/file12ig.png (http://imageshack.us)

WEEKLY:
http://img125.imageshack.us/img125/5952/file10no.png (http://imageshack.us)

[b_cadvantag]

That's gotta hurt.

The fact that it held its 50DMA is a bright spot. If that lets go there's support just above 22.

WOW


Taking pot shots.....that speaks volumes

[DSteckler]

What pot shots? I was referring to the gap open lower - that's gotta hurt the longs. Now, care to add anything substantial to the discussion?

[skiracer]

Those gaps down to $21/22 range haven't been anywhere near filled. Average daily volume is 360200. Todays volume of 2,812,874 wasn't exactly amateurs bailing out. It might recoup or it might just fill those gaps down to $21. That was a very damaging article today in the Journal of American Medical Association. If it is a buying opportunity would you buy it here or wait to see if it goes lower. I'm betting there's going to be selling into any strength shown over the short term. Being real and being patient an not speculating on what you think it will do is going to be the key but you cannot discount what that article stated and what those 2800000 shares today stated.

[Lyehopper]

Those gaps down to $21/22 range haven't been anywhere near filled. Average daily volume is 360200. Todays volume of 2,812,874 wasn't exactly amateurs bailing out. It might recoup or it might just fill those gaps down to $21. That was a very damaging article today in the Journal of American Medical Association. If it is a buying opportunity would you buy it here or wait to see if it goes lower. I'm betting there's going to be selling into any strength shown over the short term. Being real and being patient an not speculating on what you think it will do is going to be the key but you cannot discount what that article stated and what those 2800000 shares today stated.
SKIRACER!!!!

Now where in the HELL have you been?!!!!

[skiracer]

SKIRACER!!!!

Now where in the HELL have you been?!!!!

Just lurking Lye. BTW I thought that was a tremendous buying opportunity on BBD yesterday. I bought 1000 shares at $38.52. Anytime you can get into a MM pick at 2 points lower than the hugh one's own entry has to be taken as an opportunity. If it just gets back to where he bought it at $40.65 range I'll be quite happy.

[Lyehopper]

Just lurking Lye.
Great to see you posting again.... Been missing your great wisdom dude!

BTW....How's that condo project going? Setting those piles yet?

[skiracer]

Great to see you posting again.... Been missing your great wisdom dude!

BTW....How's that condo project going? Setting those piles yet?
Everything going great and moving ahead Lye.

[New-born baby]

Hi, Ski! Glad to see you back in town! :D

Now about your comments, here is my view:

Those gaps down to $21/22 range haven't been anywhere near filled. That's exactly right. I am thinking that they are runaway gaps. I could be wrong. :d

Todays volume of 2,812,874 wasn't exactly amateurs bailing out. I am not sure if they were amateurs or not. I do know that 1.4 million shares were sold, and 1.4 million shares were bought, but I don't know any of the buyers or sellers. But my point is that MYGN bounced off of support and that kept the cup and small handle on the weekly intact, and the chart formation is still valid. Support is a great place to buy, but we don't know if it will hold in the future or not. The old rule that 'support is support until it isn't' still applies. If this support breaks, we had to re-evaluate the chart and the proper course of action.

The issue of gaps is a difficult one. If the stock has sufficient momo, the gap down is a buying opportunity. MFLX is a great example; damaging article/news, a strong pullback, and an even stronger bounce. Those people that sold turned out to be wrong; those that bought were correct. Last fall ACI was a momo stock that ran to $70. Damaging downgrade resulted in a one day drop to $65. Turned out to be a great buying opportunity as the stock ran to $88. BBD: you are buying on a recent plunge down. The news that is punishing that stock is inflation. But you are buying because it is a momo stock that you think has sufficient power to overcome the news. I think you are correct.

SO the question: does MYGN have enough momo to overcome? The chart says so, and this is what I am attempting to read. The uptrend is still officially in tact because: 1. didn't bust the 50 day; 2. cup still intact; 3. known support held. But of course, nobody knows. And we just have to buy the stock and have an exit plan in case we are wrong. :D

[New-born baby]

Ski:
I think if you look at these three charts you'll see why I think MYGN still has the momo.

Here's a look at MoMo for comparison:
http://img68.imageshack.us/img68/5378/chart17pl.gif (http://imageshack.us)

http://img91.imageshack.us/img91/4654/chart25bv.gif (http://imageshack.us)

http://img68.imageshack.us/img68/394/chart33vg.gif (http://imageshack.us)

[NY4Ever]

Myriad flays media claims
Reports that breast cancer test is flawed are false, company says
By Bob Mims and Carey Hamilton
The Salt Lake Tribune



Myriad Genetics Inc., backed by market researchers, fired back Wednesday at published claims the biopharmaceutical company's test for breast cancer genes is flawed.
It was initial news reports about a University of Washington study that were misleading, Salt Lake City-based Myriad said. Analysts from Merrill Lynch and JMP Securities agreed, noting that coverage underplayed the fact that the UW research was done on a rare group of women at a particularly high risk for breast cancer.
How rare? The UW study group - 300 existing cancer patients, all of whom also had at least four or more close relatives with breast or ovarian cancers - would comprise just three-quarters of 1 percent of the tens of thousands of women who take Myriad's BRCAnalysis test annually, the company said.
"This happened in a fraction of those individuals . . . who had extremely high burdens of cancers in their families," said Gregory C. Critchfield, president of Myriad Genetics Laboratories.
The UW study, published Tuesday in The Journal of the American Medical Association, found that Myriad's test for predisposition for breast cancer missed genetic mutations linked to the disease in 10 percent to 12 percent of the study group. Women with those seldom-occurring mutations have an 80 percent chance of developing breast cancer in their lifetimes - eight times the rate for women in general.
The study was seen in some circles as increasing the pressure on Myriad Genetics, which has been the focus of critics who say its patents give it a monopoly on the test, for which it charges as much as $3,000. They argue that more thorough testing methods should be developed.
Director Saundra Buys says her High-Risk Breast Cancer Clinic at the Huntsman Cancer Institute in Salt Lake City has offered the BRCAnalysis test since its beginnings in 1996. The clinic also has provided it to many of the 1,200 people enrolled in its Breast Cancer Family Registry, 31 percent of whom were found with breast cancer mutations.
"You might feel betrayed if all you did was put out your arm and have a genetic test done for $3,000," Buys said in reference to the UW study. "But people need to have this testing done in the context of counseling and education and not in a vacuum. They should walk out of counseling and know that if the test is negative that doesn't mean they're not at high risk."
Vickie Venne, a genetic counselor at the institute, said she talked on Wednesday to four women concerned about the test. Two of them participated in the study and hadn't yet learned their results.
"We don't know everything yet. That's why we're still doing research," Venne said. "For all intents and purposes, it's still the best we have."
Analysts from both Merrill Lynch and JMP Securities echoed Myriad's concerns Wednesday as the company's stock closed


at $25.69, down 6 percent.
"Contrary to a New York Times article . . . that claimed Myriad's test for breast cancer genes is flawed, Myriad's screen is accurate and detects genetic mutations that lead to a higher risk for breast cancer in greater than 99 percent of patients tested," a trio of Merrill Lynch analysts concurred.
Charles Duncan of JMP took a similar article in The Wall Street Journal to task. "We view the data as applicable to a much smaller population than the article leads on," he wrote, adding that Myriad always has suggested additional testing for high-risk patients who get negative BRCAnalysis results.
BRCAnalysis has been done on more than 100,000 women to date, the company confirms. Using blood samples, the patented test focuses on the BRCA1 and BRAC2 genes, seeking evidence of the most commonly occurring five breast cancer-related mutations.
"We have been looking for some way to test for all [breast cancer mutations], and we're getting close to having that technology available," Critchfield said, noting available scans for remaining, rarer mutations are available for clinical researchers but so far do not meet standards for general medical marketing.
BRCAnalysis tests and other predictive medical products accounted for $23.4 million of Myriad's $27.3 million in revenue for its most recent quarter.
In a New York news conference Tuesday on the UW study, Mary-Claire King, co-author and a geneticist at the Seattle school, underscored the need to develop additional testing methods beyond Myriad's near-monopoly in the United States.
Myriad spokesman Bill Hockett countered that his company's control of the BRCAnalysis test - based on genes Myriad researchers discovered - has guaranteed a decade of quality control.
"There is no better test available today, and open competition would not provide a better test. In fact just the opposite is far more likely," he said.

[b_cadvantag]

What pot shots? I was referring to the gap open lower - that's gotta hurt the longs. Now, care to add anything substantial to the discussion?


I dont think it hurts the longs- support held. good time to buy on add to a position.

But what do I know...At least I dont jump someone's thread and hack on them.

[NY4Ever]

Interesting Reading From Another Board


Old Rivalries

Long-Term Sentiment: Strong Buy 03/23/06 11:08 am

When I read the article yesterday outlining the study conducted by Mary Claire King of the University of Washington I was reminded of the fierce rivalry that has always existed between Ms King and Mark Skolnick of Myriad Genetics. Myriad was created to attempt to isolate the gene causing inherited breast cancer and was in a competition with a group headed by Ms. King to find the gene. As we know Myriad won the race, patented the gene, and created the test for BRCA 1. For a brief period Skolnick and King worked together but the natural competition among rivals made that collaboration impossible.

My point is simply that the study as designed by Mary Claire King was created to show the flaws in the Myriad test. There was an outstanding television show on PBS a couple of years ago called DNA with an episode called "Curing Cancer", which chronicles the race for the gene and the competition between several groups including Myriad and King (while she was at UC Berkely) to locate and clone the gene. Both King and Skolnick were interviwed on the program and there is no love lost between the two of them. The obvious issue presented is the role of corporations and the stock market in the field of medical research for personal gain. An interesting comment was made by James Watson, one of the true pioneers of genetic research, who welcomes the pharmaceutical companies to the field. I think it is obvious that academic insitutions alone will not have the resources to accomplish the necessary research and it is only by creating an appropriate "Risk-Reward" balance will the public interest be served.

Clearly the debate regarding the patenting of genes will rage on with merit on both sides of the argument. I will not hazard a guess as to the eventual outcome but to me it is interesting to see how old rivalries and competitive spirit like that between King and Skolnick impact scientific discovery.

[NY4Ever]

"Panics,in some cases, have their uses; they produce as much good as hurt.
Their duration is always short; the mind soon grows through them and acquires a fIrmer habit than before." Thomas Paine

LOAD UP THE WAGON !

[NY4Ever]

The stock decline is "a buying opportunity," said Annabel Samimy, an analyst at UBS Securities LLC in New York, in a note to clients Wednesday. "We do not believe this puts Myriad's revenue growth at risk, as the tests remain an important and valid predictive tool."

[skiracer]

I dont think it hurts the longs- support held. good time to buy on add to a position.

But what do I know...At least I dont jump someone's thread and hack on them.

I think it is important to supply some technical or fundamental basis to substantiate your feelings anytime you tout a stock. Most people here usually do provide some solid argument to support their positions. Anyone can make any claim they want but if someone else takes issue with that claim and can back it up with something better than "back up the wagon" after a distribution day of nearly 3 million shares then you can't call that anything except good solid reasoning. Of course it's your money and you can do what you want with it but if you're stuck in a position with no plan or escape route it's easier to rationalize why it's still a great position and to stay in it.
None of us know what MYGN is going to do short or long term but making an educated assumption based on some solid analysis it better than empty words with no sound basis for them.

[Lyehopper]

I think it is important to supply some technical or fundamental basis to substantiate your feelings anytime you tout a stock. Most people here usually do provide some solid argument to support their positions. Anyone can make any claim they want but if someone else takes issue with that claim and can back it up with something better than "back up the wagon" after a distribution day of nearly 3 million shares then you can't call that anything except good solid reasoning. Of course it's your money and you can do what you want with it but if you're stuck in a position with no plan or escape route it's easier to rationalize why it's still a great position and to stay in it.
None of us know what MYGN is going to do short or long term but making an educated assumption based on some solid analysis it better than empty words with no sound basis for them.
He quoted "Thomas Paine" AND "Annibel Samimey" Skiracer! what else do ya need? Load up the freakin wagon dude! jejeje

[New-born baby]

He quoted "Thomas Paine" AND "Annibel Samimey" Skiracer! what else do ya need? Load up the freakin wagon dude! jejeje

Forget the stock; load up on options. JAN 07 calls. :D BUY the $25 strike for $4.20 and sell the $30 strike for $3.20. So for $1 you stand to gain $5 IF Thomas Paine is right. My only problem: Thomas Paine was a great infidel.

Pictured below is Lyehopper's Relatives with loaded wagon of MYGN shares :D
I don't know who loaded the wagon--he wasn't very good at it, that's for sure. Perhaps Annibel Samimey :D
http://img65.imageshack.us/img65/5518/file15zc.png (http://imageshack.us)

[skiracer]

Forget the stock; load up on options. JAN 07 calls. :D BUY the $25 strike for $4.20 and sell the $30 strike for $3.20. So for $1 you stand to gain $5 IF Thomas Paine is right. My only problem: Thomas Paine was a great infidel.

Pictured below is Lyehopper's Relatives with loaded wagon of MYGN shares :D
I don't know who loaded the wagon--he wasn't very good at it, that's for sure. Perhaps Annibel Samimey :D
http://img65.imageshack.us/img65/5518/file15zc.png (http://imageshack.us)

I sure there is "goji juice" packed away inside those bundles of straw

[Tatnic]

if your prices are correct, you're conclusion is not. IF the stock closes at $30 or higher on exp, your max gain is $4, not $5. Its impossible to have a gain of $5 on a $5 spread.....if it closes at $25 or lower, your max. loss is $1 (lose the entire $4.2 for the long call but keep the $3.2 for the short). Still a very good risk/reward ratio of 4:1. But, in my experience I've found that very often when such a high risk reward pops up, it never works out...not sure why. The options Gods know more than we do? Good luck, you'll need it with this stock IMO.

[NY4Ever]

Current analyst ratings: 4 strong buy 4 buy 1 hold

Stock is a bargain at current levels. A splendid buying opportunity now that we have shaken out the weak holders.

"Our doubts are traitors, and make us lose the good we oft might win by fearing to attempt." William Shakespeare

[NY4Ever]

Just for the record you won't get a lot of stock ideas from me. I only post potential homerun stocks -- not those for a quick in and out trade. In all my years on Wall Street I never knew a technician who made any real money.
The smart money on Wall Street buy stocks in their embryo stage and holds on for the big score such as was achieved by those who bought AMGN in 1988.

[NY4Ever]

Continue to accumulate. Stock is now at 25.59 unchanged on the day after reaching 26. Volume drying up which means selling has dried up. Good week next week for this stock.

[NY4Ever]

"more than 100,000 deaths and more than 2 million hospitalizations nationwide result annually from medicinal side effects, and that most medicines are developed for the "average" person.
"We don't have all the tests we need to make personalized medicine a reality," he said. "We'll have to make new tests. . . . Best-in-class technology is already available. Myriad has it. Sorenson Genomics has it. We think the key driver for personalized medicine will be the discovery of new content, new markers." From today's Deseret News

[gerihearne]

"more than 100,000 deaths and more than 2 million hospitalizations nationwide result annually from medicinal side effects, and that most medicines are developed for the "average" person.
"We don't have all the tests we need to make personalized medicine a reality," he said. "We'll have to make new tests. . . . Best-in-class technology is already available. Myriad has it. Sorenson Genomics has it. We think the key driver for personalized medicine will be the discovery of new content, new markers." From today's Deseret News

ny4ver, are you still accumulating?

[Lyehopper]

I sure there is "goji juice" packed away inside those bundles of straw
Those bundles weren't straw dude.lol

[NY4Ever]

ny4ver, are you still accumulating? >>

I am not adding to my position though I recommend those with no positions or little to at least have enough shares to make it worthwhile being in this stock. Expect MYGN to close its gap shortly and head over 30. Nothing has changed negatively in the fundamentals as time will prove.

[NY4Ever]

Please be advised that I have left the board and will no longer be able to answer any questions you might have regarding MYGN.

[jiesen]

Hi NY,

How do you think the market for chemotherapy drugs such as MYGN is developing will react if a product like this one is successfully developed?

http://www.nanospectra.com/Aurolase.htm

I am seeing a negative trend in the Insulin/Lantus market that is correspoinding to the increased use of the new diabetes therapies introduced by AMLN. I wonder how quickly a breakthrough in cancer treatment would stir things up in that area.

[gerihearne]

Please be advised that I have left the board and will no longer be able to answer any questions you might have regarding MYGN.

Sorry to see you go. All the best to you and your family,
Geri

[Tatnic]

Come on back to aol, that place needs some provacative posters to bring it back from the dead.

[New-born baby]

MYGN support failed today, and the fall has begun. Stand back.

[NY4Ever]

MYGN support failed today, and the fall has begun. Stand back.>>

The decline is basically over for MYGN but a lot of damage has been done technically to the stock. I am a buyer. That said, as I posted on another thread last week, April will give back the gains of March. A number of institutions decided to dump their bio-tech stocks this week and the selling began on Monday. Don't fight the interest rate trend.

[New-born baby]

MYGN support failed today, and the fall has begun. Stand back.>>

The decline is basically over for MYGN but a lot of damage has been done technically to the stock. I am a buyer. That said, as I posted on another thread last week, April will give back the gains of March. A number of institutions decided to dump their bio-tech stocks this week and the selling began on Monday. Don't fight the interest rate trend.

NY,
Have you thoughts about where the QQQQs are headed?

[NY4Ever]

NY,
Have you thoughts about where the QQQQs are headed?>>

39.25

[spikefader]

NY,
Have you thoughts about where the QQQQs are headed?>>

39.25I say 40.25.

[DSteckler]

Next support level for MYGN is a little over 23.

[Tatnic]

is my guesstimate.

[NY4Ever]

Myriad and Abbott Enter Into Broad Discovery Collaboration
SALT LAKE CITY, April 11 /PRNewswire-FirstCall/ -- Myriad Genetics, Inc. (Nasdaq: MYGN) (www.myriad.com) and Abbott (NYSE: ABT) (www.abbott.com) announced today that the two companies have entered into a broad drug discovery collaboration to identify novel therapeutic targets. The collaboration will leverage proprietary technology from both organizations to identify favorable targets amenable to drug discovery.

Under the five-year research agreement, Myriad will use its genetics, RNA expression profiling, and other discovery technologies, to identify human genes and regulatory networks associated with a variety of diseases. Myriad will evaluate differences in DNA and the RNA expression between thousands of individuals to identify the genetic basis of disease. Abbott will advance these genes through its chemical genomics platform to identify targets and leads for drug discovery.

Each company will have exclusive rights to the therapeutic targets and drug lead compounds to expand their therapeutic pipelines. Myriad will receive approximately 40 percent of the targets with associated lead compounds identified under the collaboration. Abbott will receive approximately 60 percent. Financial terms of the agreement were not disclosed.

"The combination of technologies achieved through this collaboration will further the drug discovery efforts at both companies and is expected to lead to innovative solutions for a wide range of unmet medical needs," said Dan Norbeck, Ph.D., Vice President, Pharmaceutical Discovery, Abbott.

"We are extremely pleased to be working with Abbott to discover the next generation of lead compounds to treat diseases with major unmet needs," said Peter Meldrum, President and CEO of Myriad Genetics, Inc. "We will apply our expertise with leading discovery technologies along with Abbott's proprietary chemical genomics platform to produce a set of novel, high-value drug targets and lead compounds

[spikefader]

NY4ever

What is your average cost price long MYGN? And where is your stop?

Good luck with the trade dude!

[NY4Ever]

What is your average cost price long MYGN? And where is your stop?

22.50 Don't use stops. Volume today disturbing. Stock could test its 200 DMA. Right now at its 100 DMA. Biotechs out of favor, but damage in MYGN
has been severe.

[DSteckler]

MYGN = deep doodoo.

Intermediate-term support line is just below today's low, around 23. Long-term support line is around 21.85.

[NY4Ever]

Article Last Updated: 04/11/2006 10:54:45 PM MDT

Myriad Genetics teams with Abbott Labs
Opportunity: The alliance will give the SLC biotech company a 40 percent share of what it produces
By Bob Mims
The Salt Lake Tribune



A new, five-year partnership with Abbott Laboratories will give Myriad Genetics something small biotechnology companies seldom get: a piece of product. It also might get the opportunity to boost its battered stock.
"It is a rather unique strategic alliance," Myriad President and CEO Peter Meldrum said Tuesday. We "usually form the [drug] compounds and receive milestone payments and up-front money, while the other companies develop drugs perhaps worth billions."
In the research-and-development pact with Abbott, Myriad will receive no initial investments or milestone incentives. Instead, the Salt Lake City company, best known for its genetic cancer predisposition tests, will receive rights to 40 percent of the compounds it helps discover.
Studies and development of drugs will aim at a wide range of diseases, from heart ailments and neurological disorders such as Alzheimer's to cancer, pain relief therapy and HIV/AIDS.
"We get some of the compounds to develop on our own," Meldrum said. "This is the wave of the future for companies like Myriad that want to eventually sell their own drugs, and not just be researchers."
The partnership announcement came along with news of a major work force shift for the company. About 80 employees of the company's "CODIS" or genetics forensics section have been notified their positions are being phased out; most of them are expected to be redeployed elsewhere within Myriad.
The company also plans to hire another 150 people by year's end, bringing its work force to 900. Some of those new hires will go to the company's R&D work with Abbott; others will complement the company's predictive medicine group and other operations.
The deal with Abbott, a $22.3 billion annual revenue company, gives Myriad ($98.5 million) a powerful friend in the pharmaceutical development industry, Meldrum said.
Together, the companies will be well positioned to "discover the next generation of lead compounds to treat diseases with major unmet needs," he said.
Shiv Kapoor, an analyst with Montgomery and Co., said the pact with Abbott "testifies [to] Myriad's potential and strength in gene and drug target discovery technologies."
Kapoor also praised Myriad's success in nailing down a 40 percent share of the results as "impressive," but added a caution that "drugs from such a collaboration

will take many years to go through trials before being approved."
Charles Duncan of JMP Securities called the pact "positive, external validation" for Myriad, though he added that the lack of financial detail made assessment of the partnership's profitability impossible.
David Webber of First Albany wrote Tuesday that the linkage with Abbott "strengthens the outlook for Myriad's long-term therapeutic pipe- line."
He went on to advise "accumulation of Myriad stock based on its strongly growing predictive medicine business [and] the higher profile of its therapeutic pipeline."
Myriad stock still continued to suffer the slide it has been on since last month, when questions were raised about the efficacy of its test for breast cancer-related genes.
Although the company has dismissed a University of Washington study as being misleading, Myriad's stock has fallen nearly $5 since the results were released in early March. Shares closed Tuesday at $23.24, down 85 cents, or 3.5 percent.
Abbott also lost ground in trading Tuesday, closing at $41.45 per share, down 43 cents and 1 percent.

[NY4Ever]

No change in opinion. 40 by end of June.

[NY4Ever]

Load up the wagon. $30 May $40 June

"Our doubts are traitors, and make us lose the good we oft might win by fearing to attempt." William Shakespeare

[NY4Ever]

Just broke out from its inverted head shoulders formation over 26. Stock remains a strong buy.

[NY4Ever]

Stock will prove a gigantic winner as today's earnings, news and conference call as evidence. You can hear the conference all by going to Myriad's web site.

I have left the board for good as I have more important things going on in my life than having to deal with a bastard like Steckler. You can have him and his sidekicks and good luck with the crap he dispenses. BTW, I have challenged this moron to a $100,000 wager that I am a retired V-P from a major Wall Strret firm. In fact, I was made a partner at age 38. Steckler hasn't the balls to take me up on this wager. He gets his kicks by driving people down and making them feel worthless. You can have him. You deserve him. Good luck !

[NY4Ever]

Today's Conference call:


Therapeutic products in development

We currently have four drug candidates in seven clinical trials and a number of drug candidates in late-stage preclinical development. Our most advanced drug development programs are described below:



• Flurizan™ (R-flurbiprofen): drug candidate for Alzheimer’s disease. Flurizan, our lead therapeutic candidate for the treatment of Alzheimer’s disease, is the first in a new class of drug candidates known as selective amyloid beta lowering agents, or SALAs. In April 2005, we completed a Phase 2 human clinical trial of Flurizan in 207 patients with mild to moderate Alzheimer’s disease. The study found that patients with mild Alzheimer’s disease who received the 800 mg twice-daily dose of Flurizan achieved between 34 and 45% slowing in decline on the three primary endpoints (activities of daily living, overall function and cognitive ability). A 20% or greater slowing in decline is generally regarded as clinically relevant. Flurizan appeared to be well tolerated by Alzheimer’s patients in the Phase 2 study and adverse events were generally mild and non-specific and did not differ significantly between placebo and treated groups. Since April 2005, we have continued a Phase 2 follow-on study, gathering longer-term data from the same patients who elected to continue beyond the 12 months of the original study.

We have also initiated enrollment in a Phase 3 study in patients with mild Alzheimer’s disease. The Phase 3 trial is a two-arm study (800 mg twice daily and placebo) that will enroll 800 patients per arm in over 130 centers in the United States and is designed to assess the ability of Flurizan to reduce the rate of cognitive decline and decline in activities of daily living in patients with mild Alzheimer’s disease over an 18 month period. Alzheimer’s disease is a degenerative neurological condition affecting up to 50% of all people aged 85 or older, with an estimated four million cases in the United States alone.



• Flurizan (R-flurbiprofen): drug candidate for prostate cancer. Flurizan is also in a Phase 2b human clinical trial for the treatment of patients with pre-metastatic prostate cancer. This clinical trial is a three arm (800 mg twice daily, 800 mg once daily and placebo), 82 patient per arm study being conducted at 56 centers in the United States and Canada and is designed to assess the ability of Flurizan to delay the onset of metastatic cancer in patients with prostate cancer. Approximately 232,000 men in the United States were diagnosed with prostate cancer in 2005. It is the second leading cause of death from cancer in men.



• Azixa™: drug candidate for solid cancer tumors and brain metastases. Azixa, also known as MPC-6827, is a novel, small-molecule tubulin inhibitor that is being studied in two Phase 1 human clinical
trials. These trials use an escalating dose regimen designed to evaluate the safety and pharmacokinetic profile of Azixa in patients with advanced solid tumors and metastatic brain tumors, respectively. In preclinical studies, Azixa showed better activity against a range of human tumors in mouse xenografts than the standard of care treatments for those cancers. In addition, Azixa demonstrated the ability to effectively cross the blood-brain barrier and was not subject to multiple drug resistance. This drug candidate has demonstrated activity in preclinical studies against tumors of the prostate, breast, pancreas, colon and skin (melanoma). According to the American Cancer Society, these cancers are expected to account for approximately 642,000 new cases in 2005 in the United States alone. In addition, according to the National Cancer Institute, it is estimated that there were as many as 170,000 new cases of brain metastases in 2005.




• MPC-2130: drug candidate for blood cancers. Our drug candidate MPC-2130, a novel apoptosis inducing small molecule, is also in the Phase 1 clinical trial stage. The study is designed to evaluate the safety and pharmacokinetic profile of MPC-2130 in patients with advanced metastatic tumors or blood cancers as well as refractory cancer that has progressed despite previous chemotherapy. In preclinical studies, MPC-2130 demonstrated cancer cell killing activity in ovarian cancer and prostate cancer as well as two lymphoma cell lines, Burkitt’s lymphoma and T-cell lymphoma. In addition, MPC-2130 was not subject to multiple drug resistance and was able to cross the blood-brain barrier. According to the American Cancer Society, approximately 98,000 Americans were diagnosed with blood cancers in 2005.



• MPC-0920: drug candidate for thrombosis. In April 2006 we initiated a Phase 1 human clinical trial for our drug candidate MPC-0920, an orally available direct thrombin inhibitor. The study uses an escalating dose regimen designed to evaluate the safety and pharmacokinetic profile of MPC-0920 in healthy volunteers. MPC-0920 has demonstrated characteristics that may offer improvements over traditional anticoagulants, which have limitations such as nonselectivity, inability to effect thrombin-bound fibrin and drug interactions. We believe that deep-vein thrombosis and arterial fibrillation represent two large potential markets.



• MPI-49839: drug candidate for AIDS. As published in the scientific journal Cell in October 2001, our scientists and their collaborators discovered the viral budding mechanism in HIV and other viruses. This discovery led to the development of MPI-49839, an orally available viral budding/maturation inhibitor, which is one of a new class of drug candidates for the treatment of AIDS. MPI-49839 has demonstrated strong anti-HIV activity and has been shown to be active against many of the drug resistant strains of HIV. MPI-49839 is in late-stage preclinical development in preparation for human clinical testing in the future, and we may submit an Investigational New Drug application, or IND, as early as the end of our fiscal year ending June 30, 2006.



• MPC-4505: drug candidate for chemotherapy induced emesis. Our drug candidate MPC-4505, a small molecule that has demonstrated solubility and oral bioavailability, is an NK1 receptor antagonist for chemotherapy induced emesis (nausea and vomiting). We believe these characteristics of MPC-4505 make it suitable for both an oral formulation and a sterile IV formulation. MPC-4505 has shown central nervous system penetration, a long half-life and a favorable safety profile in preclinical testing. MPC-4505 is in late-stage preclinical development in preparation for human clinical testing in the future.

[NY4Ever]

MYGN Last
26.86
+1.54

Looking for a new high this week. Expect upgrades.

[New-born baby]

MYGN Last
26.86
+1.54

Looking for a new high this week. Expect upgrades.

NY,
You really called a good one here.

[Gatorman]

MYGN Last
26.86
+1.54

Looking for a new high this week. Expect upgrades.
Own MYGN at 27.93. So far, so good. Waiting for the upgrades.

[NY4Ever]

Myriad Genetics "strong buy," target price raised

Wednesday, May 03, 2006 3:37:23 AM ET
JMP Securities

EW YORK, May 3 (newratings.com) - In a research note published yesterday, analysts at JMP Securities reiterate their "strong buy" rating on Myriad Genetics (MYGN.NAS). The target price has been raised from $29 to $33.

[NY4Ever]

Great close: High for the day: 27.30 52 week high of 28.09 should be taken out shortly. My only concern is that someone may try to take this company over since my 2010 target is $250.

[NY4Ever]

Just made a new 52 week high.

[NY4Ever]

Another strong day. This stock, as I have said previously, should not be traded. It is another AMGN in the embryo stage. I may not be around to see my forecast of 250 a share by 2010, but it is money in the bank. You have gotten in on the ground floor. Put the stock away and forget about it until 2010. That's my advice. Good luck !

[Lyehopper]

Another strong day. This stock, as I have said previously, should not be traded. It is another AMGN in the embryo stage. I may not be around to see my forecast of 250 a share by 2010, but it is money in the bank. You have gotten in on the ground floor. Put the stock away and forget about it until 2010. That's my advice. Good luck !
Thanks dude....

[Websman]

Great call NY!

[gerihearne]

Great call NY!

i'm likin it ...

[NY4Ever]

A bargain under 25. Novel HIV drug will enter Phase I trial later this summer.

[gerihearne]

A bargain under 25. Novel HIV drug will enter Phase I trial later this summer.

had to dig deep for this post ...
mygn now riding at 54.72 ...
anybody else still watching this one?
graciously,
geri